Palbociclib (PD-0332991) HCl

Licensed by Pfizer 製品コードS1116

Palbociclib (PD-0332991) HCl化学構造

分子量(MW):483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

サイズ 価格(税別)  
JPY 18260.00
JPY 28220.00
JPY 94620.00

カスタマーフィードバック(8)

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  •  

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

    WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

    P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

製品安全説明書

CDK阻害剤の選択性比較

生物活性

製品説明 Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
特性 Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
ターゲット
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
体外試験

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 MoC4T4lv[XOnIFHzd4F6 M{T0WFI1KGh? NEGxNZBKdmirYnn0bY9vKG:oIFPET|Qh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBT[iCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFAzKM7:TR?= M3XJNlI1PjRzMUCz
COLO205 NFq4bm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz0O2o4OiCq MkPyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB|NjFOwG0> NVLQNmtkOjR4NEGxNFM>
U937 NX3pTpJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPvNmg6PzJiaB?= MnT1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjF2IN88US=> NXH0PWRFOjR4NEGxNFM>
MOLM13 NGLjV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXO3NkBp NEj5UlhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yOyClZXzsd{Bp[XKkb4LpcochTkyWMzDJWGQhdXW2YX70JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO MXyyOFY1OTFyMx?=
MOLM13 M2HwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3pPHc4OiCq NEX3UnJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJNwemGoZX7pZk1z\XOrc4ThcpQhcHWvYX6gUW9NVTF|IHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ49zeG:{YYTpc44hd2ZiW{PIYZRpgW2rZHnu[UBqdnSxIFTORUB4cXSqIFnDOVAhd2ZiMD6wPVYh|ryP MXuyOFY1OTFyMx?=
MDA-MB-435 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PMXlI1KGh? MYDJR|UxRTBwMU[g{txO M1jwclE2QDBzOEOx
K562 M3HJcWN6fG:2b4jpZ{BCe3OjeR?= MmXYPVYhcA>? NH\1Om5FVVOR M2TGTGlEPTB;MjFOwG0> M{O4O|I1PDF5NU[2
DU145 NYrzbGtjS3m2b4TvfIlkKEG|c3H5 NFHEUZY6PiCq NEfWSGtFVVOR NYf5cJpHUUN3ME23MlUh|ryP MWCyOFQyPzV4Nh?=
MDA-MB-231 NWT6OYx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXQN21WOSEQvF2= MXKyOEBp MWLEUXNQ NYrlflZ6S2WubDDjfYNt\SCjcoLld5Qh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm M4WyUVI1PDF5NU[2
MCF7 MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq1ToZwOSEQvF2= NG\SbpkzPCCq NXLnS5NWTE2VTx?= NXyyZpVmS2WubDDjfYNt\SCjcoLld5Qh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm M2PyWVI1PDF5NU[2
MCF7 NIq3e|VMcW6jc3WgRZN{[Xl? MknPOUDPxE1? Mlf5NlQhcA>? M320e2ROW09? MYPJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFPET|Qw[3mlbHnuSFEh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBz\XSrbn;icIF{fG:vYTDwbI9{eGixconsZZRqd25iYYSgV4VzPzhy M2L5fFI1PDF5NU[2
MDA-MB-231 NWfzPZhXU2mwYYPlJGF{e2G7 NXf2ZZF1PSEQvF2= M{HPUFI1KGh? MYLEUXNQ MVnJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFPET|Qw[3mlbHnuSFEh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBz\XSrbn;icIF{fG:vYTDwbI9{eGixconsZZRqd25iYYSgV4VzPzhy NFPLSHYzPDRzN{W2Oi=>
MDA-MB-231 M4PyemZ2dmO2aX;uJGF{e2G7 NWfEPFZUOS1zMDFOwG0> NIrS[GIzPCCq NYftblFzTE2VTx?= MYHkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V? MlX4NlQ1OTd3Nk[=
MCF7 MUnGeY5kfGmxbjDBd5NigQ>? MWqxMVExKM7:TR?= NUmxV5h5OjRiaB?= MXvEUXNQ MVXkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V? MX2yOFQyPzV4Nh?=
MDA-MB-231 MVnGeY5kfGmxbjDBd5NigQ>? MWewMlUuOSEQvF2= NVnTbplOPDhiaB?= NYfzVnFXTE2VTx?= M3:2eYhieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm MVWyOFQyPzV4Nh?=
MCF7 MormSpVv[3Srb36gRZN{[Xl? MmfMNE42NTFizszN NUnnSIZYPDhiaB?= MojFSG1UVw>? NEPHRYJp[XNibn:gR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JJN2[i2JMTDwbIF{\Q>? M3rxOFI1PDF5NU[2
697 NYTKNpV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PBfmlEPTB;MUS4MlM5KG6P NHHXR5JUSU6JRWK=
P12-ICHIKAWA MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPITWM2OD17Nj6wOEBvVQ>? M4THXXNCVkeHUh?=
NB69 NXHsTVVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnpTWM2OD1zNkGuPEBvVQ>? M4HW[HNCVkeHUh?=
EoL-1 NF7DV2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTF6Nz6yOkBvVQ>? NXLJUINsW0GQR1XS
BHT-101 NGDhVo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH4TWM2OD1zOUiuNlUhdk1? M3LPVHNCVkeHUh?=
SK-NEP-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHYZ5VPUUN3ME2yNlAvODJibl2= M2LjZ3NCVkeHUh?=
MHH-NB-11 Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLDWXJYUUN3ME2yNlAvOTlibl2= NWXUNYFYW0GQR1XS
AsPC-1 M1nZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJ3Mj61N{BvVQ>? MnfJV2FPT0WU
ES1 M1HveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\kUJk3UUN3ME2yOVYvOjVibl2= NITjU3VUSU6JRWK=
LAMA-84 M3LldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFq0OG1KSzVyPUK1PE4yQSCwTR?= MVXTRW5ITVJ?
MOLT-16 NXn3OpFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXFe3V7UUN3ME2yOVgvPDlibl2= M2LFU3NCVkeHUh?=
ES7 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LVeWlEPTB;MkezMlA6KG6P NFrhWJBUSU6JRWK=
KY821 NXjsNml7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojnTWM2OD1|MUSuNUBvVQ>? MYLTRW5ITVJ?
RT-112 MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHZZ2k6UUN3ME2zNlEvODVibl2= NFv6T2VUSU6JRWK=
HL-60 M{nTV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTN2MD62OkBvVQ>? Mn\qV2FPT0WU
MOLT-4 NWTLVFJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvyZZFKSzVyPUO0OU4yOyCwTR?= Mn3vV2FPT0WU
KARPAS-45 NFLpT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTN5Nj6xOkBvVQ>? NHjvbpZUSU6JRWK=
SK-N-AS M3[1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnH3TWM2OD1|OEeuPFMhdk1? MkjJV2FPT0WU
CTB-1 M{\BZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILFT4tKSzVyPUSwOU4xOiCwTR?= MXzTRW5ITVJ?
NKM-1 MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe3eVBKSzVyPUSxNU45QSCwTR?= MWfTRW5ITVJ?
HTC-C3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofOTWM2OD12M{KuPVUhdk1? MoDkV2FPT0WU
BE-13 NHTMV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\jPGlEPTB;NES0MlI4KG6P MVTTRW5ITVJ?
KOSC-2 M33yVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLVTWM2OD12Nk[uPUBvVQ>? NYLVN5JXW0GQR1XS
NB14 NU[yNHpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjlcm1KSzVyPUS4N{42QCCwTR?= MYPTRW5ITVJ?
CAL-27 NHfuW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjoemFKSzVyPUS5OE42QSCwTR?= M2[2bXNCVkeHUh?=
H9 MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki1TWM2OD12OUWuOFMhdk1? M2roUnNCVkeHUh?=
RS4-11 M3z4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\h[ppKSzVyPUWwOE44OyCwTR?= NEDjU4xUSU6JRWK=
PA-1 Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmn4TWM2OD13MEmuPFYhdk1? MoXCV2FPT0WU
MV-4-11 MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfTXYtKSzVyPUWxN{45PSCwTR?= M322VHNCVkeHUh?=
OS-RC-2 NI\FPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT4[2xKSzVyPUWyNU43OiCwTR?= NXP6SZd{W0GQR1XS
RPMI-8226 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nHSmlEPTB;NUK2Mlg3KG6P M33sd3NCVkeHUh?=
HGC-27 M3HO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTV4ND65PUBvVQ>? MXXTRW5ITVJ?
CHP-212 M{DYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVmwVmw1UUN3ME21PVMvPTlibl2= M3z2b3NCVkeHUh?=
NB10 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTV7OT6xPEBvVQ>? NXniRWQzW0GQR1XS
HH MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzvVFVKSzVyPUW5PU41OyCwTR?= Ml7UV2FPT0WU
EW-16 M2fvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PyVmlEPTB;NkCzMlUzKG6P MWXTRW5ITVJ?
ES8 M{H1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jCd2lEPTB;NkC1MlIyKG6P NXG3RXBHW0GQR1XS
HAL-01 M37iRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\3NndwUUN3ME22NFUvPjdibl2= NHjoeYNUSU6JRWK=
A204 M{nyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4G5WGlEPTB;NkOzMlkyKG6P MVjTRW5ITVJ?
MHH-PREB-1 M3\Efmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrpeYZKSzVyPU[zOk46QSCwTR?= M3HzZnNCVkeHUh?=
EM-2 M4W3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\2TWM2OD14NUCuOlQhdk1? M3zOWHNCVkeHUh?=
BV-173 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfIVpNKSzVyPU[1Nk41QCCwTR?= M4rFS3NCVkeHUh?=
ONS-76 MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PKemlEPTB;Nke3MlgzKG6P MUHTRW5ITVJ?
KM-H2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\wTWM2OD14OUWuOVQhdk1? MWjTRW5ITVJ?
D-263MG MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7Bco1KSzVyPUexO{4yOiCwTR?= MmHZV2FPT0WU
ES3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfXU5pKSzVyPUeyPE46OyCwTR?= M1nJenNCVkeHUh?=
VA-ES-BJ MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm0d|ZIUUN3ME23N|IvOjdibl2= NX;jfoVTW0GQR1XS
NBsusSR NYXIUJJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPoc3hKSzVyPUe0Nk46QSCwTR?= MVPTRW5ITVJ?
NCI-H520 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\wd2ZzUUN3ME23OFYvPTJibl2= NG\DcGdUSU6JRWK=
ES5 NFj1VlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zLe2lEPTB;N{WyMlghdk1? NF7ydWxUSU6JRWK=
T-24 MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTd5OD63NUBvVQ>? MY\TRW5ITVJ?
SW962 NFG0cZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v2cmlEPTB;OEC4MlY{KG6P MYXTRW5ITVJ?
EW-3 NUPW[29wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r0SWlEPTB;OEC4Mlc3KG6P Mk\oV2FPT0WU
RXF393 NXywbpVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDTTWM2OD16MUKuO|khdk1? NGHkXoxUSU6JRWK=
U251 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli2TWM2OD16MUOuPFghdk1? MY\TRW5ITVJ?
CAMA-1 M4K3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTh|Mz65OEBvVQ>? MVHTRW5ITVJ?
JVM-3 M3:4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoK4TWM2OD16NUGuO|ghdk1? M1O3dnNCVkeHUh?=
COLO-800 M2nySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFizWXBKSzVyPUi5O{44QCCwTR?= NHfoXXdUSU6JRWK=
OVCAR-5 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[5U2lEPTB;OUCwMlEhdk1? MVTTRW5ITVJ?
LB1047-RCC NXuyUoNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vyUmlEPTB;OUK3MlU3KG6P MknOV2FPT0WU
SW954 NH;aPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\TTZBKSzVyPUmyPU41OSCwTR?= NXXZNpBQW0GQR1XS
J-RT3-T3-5 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTl|Nj6wOkBvVQ>? NWnnTowzW0GQR1XS
Mewo NHHmbVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O4OmlEPTB;OUO2MlYhdk1? MUPTRW5ITVJ?
NCI-H1770 Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfNfVE6UUN3ME25OFAvPTVibl2= MkDRV2FPT0WU
HO-1-N-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTl4Mj64NUBvVQ>? M3KxbHNCVkeHUh?=
HSC-3 M2DCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXZTHB{UUN3ME25OlYvPDhibl2= NXLOOG1qW0GQR1XS
TYK-nu NVvyWXJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjlUlV[UUN3ME25PVgvOjVibl2= NVnTVW5oW0GQR1XS
KYSE-150 MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFwMECwO|Yh|ryP Mk\xV2FPT0WU
SN12C MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13sNWlEPTB;MT6wNFg4PSEQvF2= M4PpSHNCVkeHUh?=
MOLT-13 NY\G[VBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rXV2lEPTB;MT6wNVQzOSEQvF2= MlzzV2FPT0WU
TE-11 NIm0S2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TUW2lEPTB;MT6wOFgyOiEQvF2= NXXuTmh6W0GQR1XS
DB M4[x[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLoZnMzUUN3ME2xMlA4Ojd|IN88US=> MXPTRW5ITVJ?
CAL-39 M2f2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFwMEe1NlIh|ryP NXG2dVlxW0GQR1XS
A3-KAW M1XrdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\DRo5zUUN3ME2xMlA5PDB6IN88US=> NWTFZnpRW0GQR1XS
CHP-134 NILUW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zqcGlEPTB;MT6xNVgxPyEQvF2= NInvc2ZUSU6JRWK=
TGW MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLOTWM2OD1zLkGyN|k2KM7:TR?= MYTTRW5ITVJ?
QIMR-WIL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzZVo1DUUN3ME2xMlE{OTN2IN88US=> NXji[IFsW0GQR1XS
NCI-SNU-1 MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTFwMU[zOVQh|ryP MnXuV2FPT0WU
CGTH-W-1 M4LNeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjJ[YFKSzVyPUGuNVcyQDZizszN M4X6R3NCVkeHUh?=
MHH-ES-1 NHnLdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwMUe5PFYh|ryP MWXTRW5ITVJ?
LB2241-RCC M4rmeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4eyS2lEPTB;MT6xPFYzKM7:TR?= NVzIdFA3W0GQR1XS
ML-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTKTWM2OD1zLkKwO|M1KM7:TR?= M{O1NXNCVkeHUh?=
COR-L23 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;xSJlGUUN3ME2xMlIzQTN|IN88US=> NW\Ke4VSW0GQR1XS
BFTC-905 NXvqVIZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwMkSyOlch|ryP NYHhS3YyW0GQR1XS
Hs-578-T MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwMkW4NVch|ryP NGPme4pUSU6JRWK=
KG-1 M3H4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzrTWM2OD1zLkK2Olg3KM7:TR?= MkDsV2FPT0WU
HEL NVKzdFdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLzTWM2OD1zLkK5N|M5KM7:TR?= NIfSZ|lUSU6JRWK=
A549 Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mli2TWM2OD1zLkK5N|k6KM7:TR?= NUD4T2h2W0GQR1XS
COLO-741 NUDPeIppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFwM{KwPFkh|ryP NWPDdoxPW0GQR1XS
PC-3 M{\Ed2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwM{WyNlEh|ryP M3G3[nNCVkeHUh?=
HOS NYrlUY9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mle2TWM2OD1zLkO1Nlk3KM7:TR?= MlzKV2FPT0WU
HT-1080 MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzWfohlUUN3ME2xMlM4PTF7IN88US=> M4LuSnNCVkeHUh?=
TE-8 MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrsZWU3UUN3ME2xMlQyPzd2IN88US=> M3\EXHNCVkeHUh?=
BHY NGTDcFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XLUWlEPTB;MT60OlkzOyEQvF2= MnXPV2FPT0WU
BB65-RCC NFvDdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLqTWM2OD1zLkWwOVI5KM7:TR?= MXjTRW5ITVJ?
HN MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofPTWM2OD1zLkW0NFcyKM7:TR?= NIjsPWVUSU6JRWK=
NCI-H441 NF;SR|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVj3dXNiUUN3ME2xMlU1QTB5IN88US=> NYDaRZhXW0GQR1XS
RPMI-8866 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XDTGlEPTB;MT61PFUxPyEQvF2= MV\TRW5ITVJ?
CAL-62 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDkTWM2OD1zLk[wPFYzKM7:TR?= MnfDV2FPT0WU
MG-63 NGrxWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPzWI1KSzVyPUGuOlE5OTNizszN Mlu3V2FPT0WU
SK-LU-1 M13IXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWr6O4NSUUN3ME2xMlYzOTV{IN88US=> M3vxfXNCVkeHUh?=
BCPAP NYezd5g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHJfVVSUUN3ME2xMlY3PDV5IN88US=> NU[1Z4g3W0GQR1XS
22RV1 M4\4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PocWlEPTB;MT62O|g1OyEQvF2= NVzw[GlRW0GQR1XS
T47D NVO1Xoc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXSTWM2OD1zLk[4NFYyKM7:TR?= MmXxV2FPT0WU
MSTO-211H NE\FTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTLTWM2OD1zLk[5OlA{KM7:TR?= NWDENoYyW0GQR1XS
DEL M2riS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH6bIVKSzVyPUGuO|AzPzNizszN M{LwenNCVkeHUh?=
H4 M2Tje2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe4b3NCUUN3ME2xMlc{OjF{IN88US=> NVfhXJk6W0GQR1XS
CAL-51 NHTwOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L5cmlEPTB;MT63OFg2PSEQvF2= M122bHNCVkeHUh?=
ABC-1 NGP0SnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTCTWM2OD1zLke4OVgzKM7:TR?= M1viNXNCVkeHUh?=
MZ2-MEL MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTPToFKSzVyPUGuO|k2PDJizszN M4XpcnNCVkeHUh?=
YKG-1 NIHSZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ja[2lEPTB;MT64NVA3OSEQvF2= MoPkV2FPT0WU
KM12 MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfCZoRKSzVyPUGuPFE3ODJizszN M4T6UHNCVkeHUh?=
L-363 NVr2fG9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLseWtvUUN3ME2xMlg4PDF{IN88US=> NWP2SoM5W0GQR1XS
KU812 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTFwOEmyPFIh|ryP NYS5XmxmW0GQR1XS
LOXIMVI NWfaZWxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXHTWM2OD1zLkmxNlI5KM7:TR?= MoCxV2FPT0WU
G-401 NGizOIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFwOUK0Nlgh|ryP MlnLV2FPT0WU
SW780 M3v6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHETWM2OD1zLkm2NlQ3KM7:TR?= NVfzcZZiW0GQR1XS
SW872 NYfyeXA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLETWM2OD1zLkm4N|Mh|ryP NHnFSmJUSU6JRWK=
NB7 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDLd2hKSzVyPUGuPVk{OjNizszN NUjpe29ZW0GQR1XS
T98G MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJwMEC2OlYh|ryP MojnV2FPT0WU
SW1710 M2TIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUWxUmhWUUN3ME2yMlA3QTR3IN88US=> M{nOVnNCVkeHUh?=
NCI-H1573 M1n6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUexO2FGUUN3ME2yMlA4Ojl6IN88US=> NVqxcWwyW0GQR1XS
KE-37 NWTkSXlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGn5NWtKSzVyPUKuNFg6PTFizszN MnP5V2FPT0WU
786-0 NV3jS5RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDySoZKSzVyPUKuNVU1OzlizszN MW\TRW5ITVJ?
SAS M334V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJwMkCzO|Qh|ryP MVzTRW5ITVJ?
CAL-54 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K2W2lEPTB;Mj6yNFQyOyEQvF2= M4rrS3NCVkeHUh?=
SF268 NHj2NldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPLZodKSzVyPUKuNlMyOjJizszN MWDTRW5ITVJ?
SW620 NIHZVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJwMk[xOlkh|ryP NXfq[JpYW0GQR1XS
MN-60 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfsSGJKSzVyPUKuN|ExPiEQvF2= M2LkWXNCVkeHUh?=
EFO-27 Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJwM{KwOVgh|ryP NXvBfJNzW0GQR1XS
NCI-H747 NFvyXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rqTWlEPTB;Mj6zNlE6QSEQvF2= MUnTRW5ITVJ?
HCC2218 NWDETFJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4K3NGlEPTB;Mj6zOVM4PCEQvF2= NF3ZToxUSU6JRWK=
MIA-PaCa-2 NGOyV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[xTWM2OD1{LkO2OFM4KM7:TR?= NYq3XVhpW0GQR1XS
SJSA-1 MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJwM{e3PVYh|ryP M1z0RXNCVkeHUh?=
RKO M3rX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfuTWpKSzVyPUKuN|g1QTZizszN M1[4S3NCVkeHUh?=
NB6 NIHpSlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLuN4ZKSzVyPUKuOFA{PzRizszN MlXvV2FPT0WU
ES4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTicldwUUN3ME2yMlQ2PDJ{IN88US=> NVf5bWdWW0GQR1XS
EGI-1 M4XuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m5VWlEPTB;Mj60Olg5OyEQvF2= Mk\OV2FPT0WU
CTV-1 NXPJW5FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjyTWM2OD1{LkWyO|c{KM7:TR?= NEXEWFhUSU6JRWK=
NCI-H1355 NUHqdIZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJwNUW5OVEh|ryP MXHTRW5ITVJ?
GT3TKB M{L6W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\vN|dTUUN3ME2yMlU6OTl7IN88US=> NYLYZ5doW0GQR1XS
SK-HEP-1 NF\xUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nkN2lEPTB;Mj61PVI3PiEQvF2= NXHFO4IzW0GQR1XS
GAMG MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJwNUmzPVQh|ryP MkP6V2FPT0WU
SK-MES-1 M3OxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvOR216UUN3ME2yMlYyQDB|IN88US=> NXjmNWZHW0GQR1XS
RO82-W-1 Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\ncHRKSzVyPUKuOlIxPTdizszN NXrSPYlPW0GQR1XS
ECC10 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXRR5lKSzVyPUKuO|AzODZizszN M1nxRnNCVkeHUh?=
MCF7 MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj5RZdKSzVyPUKuO|E1PjRizszN NHzJeXJUSU6JRWK=
D-283MED NW\vNVZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETyRpBKSzVyPUKuO|I1OyEQvF2= Mo[yV2FPT0WU
RPMI-7951 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnmWGNGUUN3ME2yMlc2Pjl2IN88US=> M3XXRnNCVkeHUh?=
Ramos-2G6-4C10 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\VfGlEPTB;Mj63O|A6QSEQvF2= MlX0V2FPT0WU
KGN MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjPTWM2OD1{LkixPFg1KM7:TR?= Mo\BV2FPT0WU
NUGC-3 M2K2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLvOJZKSzVyPUKuPFI2ODVizszN Mo\DV2FPT0WU
NCI-H292 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;BXWlEPTB;Mj64OVA2OyEQvF2= M{HUZ3NCVkeHUh?=
Becker NYXUXFVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jyXGlEPTB;Mj65OVg{OiEQvF2= NXftOpRsW0GQR1XS
NCI-H1299 NXTkeGRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TOTmlEPTB;Mz6wOVI3OyEQvF2= NXvHPYVwW0GQR1XS
ETK-1 MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLneVVKSzVyPUOuNFU1OyEQvF2= MYXTRW5ITVJ?
TK10 NIDsSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnLTWM2OD1|LkKwNVY2KM7:TR?= M1\oU3NCVkeHUh?=
VMRC-RCZ M4flS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTNwM{[0PFgh|ryP NXXEcJBXW0GQR1XS
YH-13 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYqyNZFmUUN3ME2zMlQ1ODd7IN88US=> NUCwc|hvW0GQR1XS
DU-145 M1rXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DjUmlEPTB;Mz60OlI3QSEQvF2= MUjTRW5ITVJ?
SW1088 MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX34cWJEUUN3ME2zMlQ4PDdizszN MnPuV2FPT0WU
HOP-92 M1Pp[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\PWndmUUN3ME2zMlUxOzR{IN88US=> NVy5cHh7W0GQR1XS
KP-N-YS NFOzVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWS0e4xIUUN3ME2zMlYzOTN7IN88US=> M{X0NnNCVkeHUh?=
NCI-H460 NW[5ZZZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:xVmlEPTB;Mz62Olc{KM7:TR?= NW\GT4pEW0GQR1XS
U-2-OS M3rNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrFTWM2OD1|LkeyOVM2KM7:TR?= NVT3SFM{W0GQR1XS
A101D NWqwNogxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jEOWlEPTB;Mz63Olk{PiEQvF2= MlnFV2FPT0WU
MDA-MB-231 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTNwOEG5OVEh|ryP MUfTRW5ITVJ?
IST-MES1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\OTWM2OD1|LkizNkDPxE1? Mn65V2FPT0WU
COR-L105 M3fqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrFNlQxUUN3ME20MlAyQCEQvF2= NID0cY9USU6JRWK=
NCI-H1437 NFjhcmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTDXmxtUUN3ME20MlAzOzB{IN88US=> M17mVnNCVkeHUh?=
CAL-85-1 NVvw[Yg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D4RmlEPTB;ND6wNlQ3OSEQvF2= M4\iTnNCVkeHUh?=
MZ1-PC NHPXdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkKzTWM2OD12LkG4OVU3KM7:TR?= MlXDV2FPT0WU
VM-CUB-1 Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXW2cFE2UUN3ME20MlMyOjh2IN88US=> NIDHOoJUSU6JRWK=
CHL-1 NEPBRWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnwOJcyUUN3ME20MlMzOTZ7IN88US=> MYjTRW5ITVJ?
MDA-MB-361 M{XTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr3VmpKSzVyPUSuN|MyPTNizszN NWjFcmJVW0GQR1XS
NCI-H661 NHPpV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz2U2tKSzVyPUSuOVAxQTJizszN NGHrV5BUSU6JRWK=
EW-11 NIjrPI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[1OZVKSzVyPUSuOVIzOzFizszN NGjjN2lUSU6JRWK=
BEN MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTRwNUK4NVUh|ryP Mor3V2FPT0WU
BFTC-909 NXfYc|VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTRwNU[yO|Uh|ryP MXvTRW5ITVJ?
NCI-H2087 M3zDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTRwNUixOlQh|ryP NVWzRol[W0GQR1XS
RVH-421 NGjzcndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Lx[mlEPTB;ND62OlY6KM7:TR?= NED3OWZUSU6JRWK=
P30-OHK M{nSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTRwNkiwNFgh|ryP MX\TRW5ITVJ?
NCI-H28 NXf3cZc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XV[GlEPTB;ND64NVY3OSEQvF2= NYTzWHZTW0GQR1XS
ES6 NGf0ZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M36xWWlEPTB;ND64N|AyPiEQvF2= M{nrT3NCVkeHUh?=
769-P M4HSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TOb2lEPTB;ND64OVkzPiEQvF2= Ml\OV2FPT0WU
OE33 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTRwOEixOlEh|ryP NHLIWHhUSU6JRWK=
SW982 M{DLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPOXVdOUUN3ME20Mlk2ODZzIN88US=> NX7Sc4g5W0GQR1XS
A388 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DDc2lEPTB;NT6wNlk5OyEQvF2= M330V3NCVkeHUh?=
TI-73 Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoSzTWM2OD13LkC2NVk1KM7:TR?= NWPtWXkzW0GQR1XS
HCT-116 MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTVwMEm4PFkh|ryP M2LIcXNCVkeHUh?=
HuP-T3 NF7UeXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zqdmlEPTB;NT6xPFcxQSEQvF2= NH;od4NUSU6JRWK=
G-402 NH[wN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjIXZlDUUN3ME21MlE6PDF4IN88US=> NYWxN5lFW0GQR1XS
NCI-H1792 NU\ZelZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ToO2lEPTB;NT6yOFYzOiEQvF2= NFLjSIFUSU6JRWK=
NCI-H209 MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknsTWM2OD13LkK1PVQzKM7:TR?= M1fPU3NCVkeHUh?=
NCI-H1650 NH3OdoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1T4XGlEPTB;NT6zNFY{PCEQvF2= NGSzTWRUSU6JRWK=
LCLC-97TM1 Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjjOFBbUUN3ME21MlMyQDB6IN88US=> M4q5Z3NCVkeHUh?=
S-117 NEXXdY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTVwM{[5O|Yh|ryP NYj0fZdwW0GQR1XS
GI-ME-N MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfGd2tJUUN3ME21MlM6PjhzIN88US=> MojNV2FPT0WU
NCI-H2122 MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXP[XVoUUN3ME21MlQ6Ozl5IN88US=> MkHLV2FPT0WU
NCI-H1793 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjQTWM2OD13Lk[3OVk{KM7:TR?= MkH2V2FPT0WU
C2BBe1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHzTGJKSzVyPUWuO|AxQDhizszN MlLOV2FPT0WU
TE-12 MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37KR2lEPTB;NT64NFU2PiEQvF2= NGDG[o1USU6JRWK=
LCLC-103H MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;uOFkzUUN3ME21MlkyPyEQvF2= MnfHV2FPT0WU
A673 MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnNTWM2OD13LkmxPVMzKM7:TR?= MlzZV2FPT0WU
BB30-HNC NUH3e4E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HLbGlEPTB;NT65PFM3KM7:TR?= NVX5WIVkW0GQR1XS
SF295 MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXqOmhKSzVyPU[uNFA1OjJizszN NIXIfIxUSU6JRWK=
KU-19-19 Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTZwMEG3N|Eh|ryP NW\TcYY5W0GQR1XS
CFPAC-1 NUDtfnpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTKTWM2OD14LkC0OFQ{KM7:TR?= M33EcXNCVkeHUh?=
LoVo MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;xVnpKSzVyPU[uNFUxPjNizszN NFKwTXNUSU6JRWK=
8505C M4\TN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH4TWM2OD14LkC3OVc{KM7:TR?= MV\TRW5ITVJ?
GMS-10 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTZwMUWwNFIh|ryP NGWzbJpUSU6JRWK=
Ca9-22 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7y[|RHUUN3ME22MlE3PzFizszN NHrVbXBUSU6JRWK=
DOK MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLWS25PUUN3ME22MlIzODd{IN88US=> NFW1fHVUSU6JRWK=
FADU M{e3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnYTWM2OD14LkK2NFM6KM7:TR?= MXvTRW5ITVJ?
BxPC-3 M1rEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTZwMkezNkDPxE1? MkHUV2FPT0WU
CAL-33 M4jGcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTZwMkmyNFEh|ryP Mn71V2FPT0WU
SHP-77 NULnWXloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX1UVNsUUN3ME22MlMyPTF{IN88US=> MWPTRW5ITVJ?
LXF-289 M1O1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{OxdWlEPTB;Nj6zN|Q2PSEQvF2= NFvHeG9USU6JRWK=
GB-1 Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TJ[2lEPTB;Nj6zPFIh|ryP NGHIdYhUSU6JRWK=
KS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTXXG1KSzVyPU[uN|g1PDdizszN MlX0V2FPT0WU
D-502MG Mk\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13GR2lEPTB;Nj60NlM4PiEQvF2= Ml3hV2FPT0WU
LAN-6 NYDXO4U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTZwNUGwNlMh|ryP NUPsXFBpW0GQR1XS
H-EMC-SS MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\HTWM2OD14LkW2NVQ4KM7:TR?= NYL0b3o4W0GQR1XS
LC-2-ad MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXNN25JUUN3ME22MlYxODd4IN88US=> MnvKV2FPT0WU
NCI-H1693 MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Dzb2lEPTB;Nj62NlIyPSEQvF2= M1rSd3NCVkeHUh?=
SK-N-FI MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDPTWM2OD14Lke1NFQ1KM7:TR?= NIT3c5VUSU6JRWK=
D-423MG NFrYUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmizTWM2OD14Lke2NVE4KM7:TR?= NWfIc3RrW0GQR1XS
KNS-42 NHjNTZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTZwN{ixPVch|ryP M2T6UnNCVkeHUh?=
GCT M3X1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWriNnRyUUN3ME22Mlk{QCEQvF2= M3SySHNCVkeHUh?=
DSH1 MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVSy[YJGUUN3ME23MlA3OzNizszN MlPVV2FPT0WU
D-247MG M1rvNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3wdXFUUUN3ME23MlA4QDhzIN88US=> MkjZV2FPT0WU
NCI-SNU-5 MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTYXIxsUUN3ME23MlE5OzdzIN88US=> MWDTRW5ITVJ?
TE-6 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\TTJl2UUN3ME23MlIxPjBzIN88US=> NWHxN3NLW0GQR1XS
NOMO-1 MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nEcmlEPTB;Nz6yNlEzPyEQvF2= NV;5[mE3W0GQR1XS
NB17 NHzkSnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jTTmlEPTB;Nz6zNFMxQSEQvF2= MnrCV2FPT0WU
EW-22 M17ndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XmWGlEPTB;Nz6zOFM1QCEQvF2= NIjyS2NUSU6JRWK=
EW-13 NWnaRlVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\FTWM2OD15LkO1NVYzKM7:TR?= Mlq0V2FPT0WU
DOHH-2 MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzl[IxKSzVyPUeuOFQxOiEQvF2= MWLTRW5ITVJ?
TGBC1TKB M{\aTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTdwNEm4PVkh|ryP NGXaS|BUSU6JRWK=
GR-ST NGrMNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjSTWM2OD15LkWyOVk1KM7:TR?= MmGyV2FPT0WU
KYSE-520 NGOyVHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTdwNUW1NVUh|ryP MlrTV2FPT0WU
CAPAN-1 MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTdwNUm1NUDPxE1? NX63dZpoW0GQR1XS
HCE-4 M37KXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvLclRKSzVyPUeuOlIzPzlizszN NVflOG1qW0GQR1XS
MLMA MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV63clRyUUN3ME23MlYzQTV5IN88US=> MnfrV2FPT0WU
HT-144 NVTw[FhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPaNnMxUUN3ME23MlY2OzZ6IN88US=> MWfTRW5ITVJ?
KYSE-180 NHO5R21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTdwN{GxOlkh|ryP MYTTRW5ITVJ?
TE-5 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTjTWM2OD15Lkm1PVcyKM7:TR?= M2TmNnNCVkeHUh?=
IGROV-1 M3TIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13j[mlEPTB;Nz65PFU2OSEQvF2= NH\3WW5USU6JRWK=
NCI-H1581 NYDQd25PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHWNmNQUUN3ME24MlAyOiEQvF2= M1HpbXNCVkeHUh?=
SW1990 MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;JZmNKSzVyPUiuNFQ3PTlizszN M{DFZ3NCVkeHUh?=
EFM-19 M2DpN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRThwMEi1OFUh|ryP NHHoZmxUSU6JRWK=
OGR-1 M3i3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGraOIRKSzVyPUiuOFMxOjNizszN NFPMRmpUSU6JRWK=
U-118-MG Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRThwNEO0OlMh|ryP MVzTRW5ITVJ?
SK-OV-3 NUjtc3F[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXMOnNtUUN3ME24MlQ3PzZ3IN88US=> MmDMV2FPT0WU
KNS-62 MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPMc49KSzVyPUiuOVE4PjFizszN NHe4b4JUSU6JRWK=
GOTO M4TvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDTTWM2OD16LkW3OlM2KM7:TR?= Mnm3V2FPT0WU
8305C NWPsPVRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRThwN{C0PFQh|ryP NXXEPVBYW0GQR1XS
RPMI-2650 NFXWfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\LVWlEPTB;OD63NVk2PSEQvF2= NWTwfZh6W0GQR1XS
NEC8 NX\MNY9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml63TWM2OD16Lke0N|A4KM7:TR?= M4C3NHNCVkeHUh?=
KYSE-450 NFvOT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXsRXJKSzVyPUiuPFY2PDhizszN MoPjV2FPT0WU
RMG-I MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjlR25YUUN3ME25MlE1ODV6IN88US=> MXLTRW5ITVJ?
CAKI-1 NHnSO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC1TWM2OD17LkOxPVc6KM7:TR?= MXLTRW5ITVJ?
KYSE-510 NVTwZ2w2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjEe2ZKSzVyPUmuN|U4PzhizszN MX3TRW5ITVJ?
A4-Fuk MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXncmVKSzVyPUmuN|Y4ODFizszN M4HBRnNCVkeHUh?=
AN3-CA MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrMXVRKSzVyPUmuOFU1PDRizszN MWXTRW5ITVJ?
SK-N-DZ MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT5TWM2OD17LkeyPFQ6KM7:TR?= MmO4V2FPT0WU
HSC-2 NH\a[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\XOGlEPTB;OT63OlYzQSEQvF2= MkLpV2FPT0WU
EW-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nnfWlEPTB;OT63PVM3QSEQvF2= MX;TRW5ITVJ?
D-566MG NVHXSVNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjBVlVKSzVyPUmuPFM3PjRizszN Mon2V2FPT0WU
COLO-792 MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHlTWM2OD17Lkm4O|Q3KM7:TR?= Mk\xV2FPT0WU
TE-10 NXLp[WdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPvTWM2OD1zMD6wN|k3KM7:TR?= NVj4OXkxW0GQR1XS
NCI-H650 MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFyLkSyPFYh|ryP NVXnNYR2W0GQR1XS
U-266 NF;ONXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4S5cWlEPTB;MUCuOFU2KM7:TR?= NELUT4VUSU6JRWK=
Detroit562 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr3OG1KSzVyPUGxMlA2OTVizszN MVLTRW5ITVJ?
NH-12 NF;IS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml34TWM2OD1zMT6xOFQ3KM7:TR?= MX;TRW5ITVJ?
CO-314 NFrBS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXOVotFUUN3ME2xNU4zQDR{IN88US=> MVPTRW5ITVJ?
IST-MEL1 Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;LVGlEPTB;MUGuOVMzOyEQvF2= NEDycIdUSU6JRWK=
KNS-81-FD MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfhSZZKSzVyPUGxMlU2OjdizszN NISwdXhUSU6JRWK=
SW1463 M1\i[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYq4e2IyUUN3ME2xNU42QTh7IN88US=> MmP2V2FPT0WU
NCI-H23 M1nSbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXqR5JwUUN3ME2xNU43PTV{IN88US=> Mn71V2FPT0WU
SK-MEL-2 M2\ocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ewRWlEPTB;MUGuO|E6PyEQvF2= MVjTRW5ITVJ?
NB13 M3O1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTF{LkG0PVUh|ryP NGPMWJVUSU6JRWK=
Daoy M33rZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1SycWlEPTB;MUKuNlg2PiEQvF2= Mn;XV2FPT0WU
NCI-H1623 Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXGT4xKSzVyPUGyMlM5ODFizszN MmLXV2FPT0WU
NMC-G1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf5b41iUUN3ME2xNk44OTdizszN MonkV2FPT0WU
DK-MG M4\6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\JTWM2OD1zMj65OFgzKM7:TR?= NV;RVIJZW0GQR1XS
TCCSUP NETWZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DMWGlEPTB;MUOuNVI5PCEQvF2= NXjjNZdVW0GQR1XS
SCC-15 MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\jNIFEUUN3ME2xN{4zPjVzIN88US=> MkX1V2FPT0WU
NOS-1 NWTab4s6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTHXW5xUUN3ME2xN{4zQDl|IN88US=> MV;TRW5ITVJ?
RH-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fze2lEPTB;MUOuN|A{PyEQvF2= MnvSV2FPT0WU
SK-MEL-3 NH7HUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkW0TWM2OD1zMz6zO|I5KM7:TR?= NF70dVBUSU6JRWK=
NB5 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrWWJY{UUN3ME2xN{41ODZ5IN88US=> NFfyPYJUSU6JRWK=
SNU-387 MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFruWHVKSzVyPUGzMlUxPzJizszN NFzXfIhUSU6JRWK=
CAL-120 NEDHUY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PZOmlEPTB;MUOuOlcyQCEQvF2= NH;IbVdUSU6JRWK=
Mo-T NY\UXI9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF|LkewO{DPxE1? NFTNU2NUSU6JRWK=
LNCaP-Clone-FGC Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jLOGlEPTB;MUOuO|k6OiEQvF2= NXK0R4ZwW0GQR1XS
CAN MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF2LkCyPFgh|ryP M2C3N3NCVkeHUh?=
SK-MEL-30 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorVTWM2OD1zND6wOlMh|ryP Mmf3V2FPT0WU
COLO-678 M13XcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;oTWM2OD1zND6wPFIzKM7:TR?= NVXDZ3N3W0GQR1XS
SCC-9 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[xcmVoUUN3ME2xOE4yODJzIN88US=> NH7vNpFUSU6JRWK=
KINGS-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\pdZpLUUN3ME2xOE4yPDB{IN88US=> NWW5XHM5W0GQR1XS
SL-513 NEDxOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF2LkG4O{DPxE1? MonlV2FPT0WU
HLE MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2L5WWlEPTB;MUSuN|g2OiEQvF2= NXq5V5lnW0GQR1XS
SW1573 NX3DTmpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\tTWM2OD1zND60OFM2KM7:TR?= NX74eWZKW0GQR1XS
KYSE-140 NWDE[5NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLSTWM2OD1zND62N|I4KM7:TR?= MUHTRW5ITVJ?
SK-PN-DW NWmwNXB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvwVZVHUUN3ME2xOE45ODBzIN88US=> MUHTRW5ITVJ?
A253 M4nXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnHeYlOUUN3ME2xOU4xPjJ3IN88US=> MonDV2FPT0WU
CAL-12T MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnT[JFIUUN3ME2xOU41PjZ{IN88US=> M2DOXHNCVkeHUh?=
COLO-679 M4\iXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL4S5RKSzVyPUG1Mlc3QDNizszN MoT0V2FPT0WU
UACC-257 M1\kOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTF4LkGyNFEh|ryP MYjTRW5ITVJ?
U-87-MG MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln2TWM2OD1zNj6zOVI{KM7:TR?= Mm\DV2FPT0WU
HCC1806 Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTF4LkewO|Eh|ryP Ml\LV2FPT0WU
NCI-H2170 NIjpRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\2c2pKSzVyPUG3MlI1PDhizszN NV3tV3lyW0GQR1XS
AGS M4i4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXxPVRCUUN3ME2xO{4{QDB6IN88US=> MnPlV2FPT0WU
MEL-HO Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF5Lke1NFMh|ryP M4LYRnNCVkeHUh?=
SW48 M1O4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3tbFZ1UUN3ME2xO{44PzF4IN88US=> NHvyS4xUSU6JRWK=
HuP-T4 NX\HO4xYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnSO2dKSzVyPUG4MlAzODZizszN MYXTRW5ITVJ?
NCI-H720 NYDYc|JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPJTWM2OD1zOD6xOFAzKM7:TR?= MWjTRW5ITVJ?
RCC10RGB NF7idGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTF6LkG2PVch|ryP M3rPRnNCVkeHUh?=
HD-MY-Z MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDhbGNKSzVyPUG4MlIzPTRizszN M1;w[XNCVkeHUh?=
A427 MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjvTWM2OD1zOD61NFk1KM7:TR?= NEXOZplUSU6JRWK=
HCC2998 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF6Lk[wOVEh|ryP NGLKOGpUSU6JRWK=
EPLC-272H MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rjV2lEPTB;MUmuNFQ{PCEQvF2= M33hRXNCVkeHUh?=
C32 NIfI[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfofVNKSzVyPUG5MlA1PSEQvF2= M1PzVXNCVkeHUh?=
UMC-11 NFLLToFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr6S5d{UUN3ME2xPU4zOTJ|IN88US=> Ml;6V2FPT0WU
CaR-1 M4\PN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTOTWM2OD1zOT62PFA1KM7:TR?= MlHTV2FPT0WU
KYSE-410 M1;OPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf4OHNKSzVyPUG5MlkyOzlizszN MXjTRW5ITVJ?
HuCCT1 MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:wUGlEPTB;MkCuOlI6PCEQvF2= MUTTRW5ITVJ?
LB996-RCC MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke5TWM2OD1{MD63NVY5KM7:TR?= NYnOVZY{W0GQR1XS
KYSE-70 MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLzTWM2OD1{MD64NFU6KM7:TR?= MmrBV2FPT0WU
CAL-72 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX4TFl5UUN3ME2yNE46OTVizszN M36zZXNCVkeHUh?=
Capan-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTJzLkC0NVMh|ryP NW\udYIzW0GQR1XS
PANC-08-13 MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke5TWM2OD1{MT6yOVE2KM7:TR?= M2[2OHNCVkeHUh?=
SBC-1 NXnN[|hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm2TWM2OD1{MT6zNFgyKM7:TR?= NITXUIxUSU6JRWK=
MFM-223 NHr5OZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfsOnRKSzVyPUKxMlM{PDJizszN Mn7pV2FPT0WU
BB49-HNC M1r5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoWxTWM2OD1{MT61O|E3KM7:TR?= Mke4V2FPT0WU
SH-4 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fFR2lEPTB;MkGuOlYyQCEQvF2= NUD0fJpDW0GQR1XS
HuO9 Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHpPY1KSzVyPUKxMlk5OjVizszN MVPTRW5ITVJ?
AM-38 MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj6THRKSzVyPUKyMlA1QDVizszN MUXTRW5ITVJ?
A431 MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPRU4gxUUN3ME2yN{4zOTF7IN88US=> MX\TRW5ITVJ?
YAPC MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vvdGlEPTB;MkOuNlY2OSEQvF2= MkDEV2FPT0WU
LU-139 NH7hNI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTWdXNYUUN3ME2yN{41QDB7IN88US=> NHzBSoFUSU6JRWK=
HEC-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfRTWM2OD1{Mz60PVM4KM7:TR?= NUTGUFZkW0GQR1XS
SCC-25 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z4PGlEPTB;MkSuN|AxPiEQvF2= NXvmXmRVW0GQR1XS
HT-29 M2nHOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T3fGlEPTB;MkSuN|gzOyEQvF2= NVHINIhIW0GQR1XS
PC-14 M1XONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYSzOJdEUUN3ME2yOE43PTdzIN88US=> NFvmcHVUSU6JRWK=
Calu-6 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnITWM2OD1{NT61NFcyKM7:TR?= MlGwV2FPT0WU
SJRH30 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrEWIVKSzVyPUK1MlY1QTZizszN M332WnNCVkeHUh?=
ChaGo-K-1 NEDzeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\NUlNKSzVyPUK2MlE3OjlizszN MXHTRW5ITVJ?
IA-LM MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJ4LkO2OFUh|ryP NFHFNnJUSU6JRWK=
GP5d MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y2NWlEPTB;Mk[uOFQ6OSEQvF2= M4n0fHNCVkeHUh?=
NCI-H2291 M3yw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M374R2lEPTB;Mk[uOlU1OSEQvF2= NXrPe2R2W0GQR1XS
BALL-1 NEjN[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXOTWM2OD1{Nj65N|k4KM7:TR?= NWXtboxyW0GQR1XS
HCC1954 NXvCbYhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvKTWM2OD1{Nj65PFA5KM7:TR?= NIjVUZpUSU6JRWK=
NCI-H2452 NI\Ud2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1W2R2lEPTB;MkeuOFE3OyEQvF2= MXrTRW5ITVJ?
LU-99A NGj0T3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP1OYhKSzVyPUK3MlU2QDJizszN MVTTRW5ITVJ?
NTERA-S-cl-D1 NH3WUYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJ5LkeyPVkh|ryP M2qyRnNCVkeHUh?=
PANC-10-05 M4HsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjBTWM2OD1{Nz63O|c2KM7:TR?= NU\ENpFZW0GQR1XS
NCI-H2405 MlLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJ5LkmzPFch|ryP NIH0b2hUSU6JRWK=
MDA-MB-415 MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHiTWM2OD1{OD60NVM4KM7:TR?= M2j1XHNCVkeHUh?=
NCI-H2342 M4rqVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3FRmxKSzVyPUK4MlUzQDFizszN MVHTRW5ITVJ?
TGBC24TKB M4XmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D1UGlEPTB;MkiuO|EyPyEQvF2= MlvXV2FPT0WU
LU-134-A M4H0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3OT3FCUUN3ME2yPE46OjZzIN88US=> MWHTRW5ITVJ?
SCC-4 NFnnb|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTNzLkC0PVQh|ryP NHm0dpBUSU6JRWK=
Saos-2 M4jMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LJdmlEPTB;M{GuPVMxPiEQvF2= NUPSU29uW0GQR1XS
RERF-LC-MS NULQcm1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkmzTWM2OD1|Mj64NlMyKM7:TR?= MWPTRW5ITVJ?
M14 NUXu[3Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL3TWM2OD1|Mj65O|Y1KM7:TR?= NF3QUGZUSU6JRWK=
HPAF-II MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\rTWM2OD1|Mz61NFEyKM7:TR?= M3m0b3NCVkeHUh?=
NCI-H1755 M{nGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTN2LkOzNFUh|ryP MXjTRW5ITVJ?
D-392MG NEjPW4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnruTWM2OD1|NT64Olc1KM7:TR?= MXLTRW5ITVJ?
A704 NIe1TpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXTTWM2OD1|Nj6wOFI4KM7:TR?= MWnTRW5ITVJ?
CP50-MEL-B MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3NTWM2OD1|Nj6xPVEyKM7:TR?= MWTTRW5ITVJ?
EW-18 NF7vWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPQ[4pKSzVyPUO2MlQ2OiEQvF2= MmPvV2FPT0WU
WM-115 Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonITWM2OD1|Nj64NFk6KM7:TR?= NVfySlJIW0GQR1XS
LU-65 NGDhWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnm[5JKSzVyPUO3MlE1OTdizszN MWTTRW5ITVJ?
NCI-H1563 NUnFWY1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\MTWlEPTB;M{euNlQ5PCEQvF2= NUfEdlRUW0GQR1XS
DBTRG-05MG NEW5N2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LKPWlEPTB;M{iuNFY6OSEQvF2= MmDMV2FPT0WU
NCI-H630 M17nb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\xTWM2OD1|OD60O|E1KM7:TR?= M4jXSnNCVkeHUh?=
NCI-H1155 NWXNbW5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjYdGpKSzVyPUO5MlI1OiEQvF2= NYHPcVZyW0GQR1XS
OVACR-3 NFHiOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH2S3BKSzVyPUO5MlkyQTVizszN NWHMeFN[W0GQR1XS
OAW-42 MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17HeWlEPTB;NECuOFI2QCEQvF2= MXfTRW5ITVJ?
JVM-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXX[lNWUUN3ME20NU4zPDF3IN88US=> M4[0NXNCVkeHUh?=
C3A NVHZc4hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTRzLkO0OFch|ryP M3q0R3NCVkeHUh?=
HT55 NFvNOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4T4N2lEPTB;NEKuNlg1OSEQvF2= M1LmVnNCVkeHUh?=
OVCAR-4 M1qwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ntcmlEPTB;NEKuNlk4PCEQvF2= MmOxV2FPT0WU
MEG-01 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr2TWM2OD12Mj60OlE3KM7:TR?= NXP3ZVJTW0GQR1XS
NCI-H82 NHPXc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTR|Lkm4PVIh|ryP NH3IOFVUSU6JRWK=
JEG-3 MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDONIhOUUN3ME20OE46PDdizszN M1zhRnNCVkeHUh?=
BPH-1 NUPWSm11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHPTWM2OD12Nj6zPVk5KM7:TR?= MlL1V2FPT0WU
MPP-89 NFXRO|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTR5LkK4PVgh|ryP Mn;XV2FPT0WU
ALL-PO MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTR5LkSxPFgh|ryP MULTRW5ITVJ?
HT MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTR5LkS5NkDPxE1? MUDTRW5ITVJ?
NCI-H2347 M1\vdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPoUJFKSzVyPUS4MlA4OTVizszN MkTvV2FPT0WU
A2780 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K2WWlEPTB;NEmuOFIzQCEQvF2= NGLaSHBUSU6JRWK=
KARPAS-299 NEK4VlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLLTWM2OD12OT61NVE6KM7:TR?= Ml33V2FPT0WU
NCI-H1651 M3TRVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPSTWM2OD12OT64PFIyKM7:TR?= Mn7zV2FPT0WU

多くの細胞株試験データを見る場合、クリックしてください

体内試験 PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
細胞試験:

[1]

+ 展開
  • 細胞株: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • 濃度: 0.01-1 μM
  • 反応時間: 24 hours
  • 実験の流れ:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • 製剤: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • 投薬量: 0-150 mg/kg
  • 投与方法: Given by gavage
    (参考用のみ)

溶解度 (25°C)

体外 Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
体内 左から右までの手順で、溶剤を製品に加えることです:
Saline
20 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 483.99
化学式

C24H29N7O2.HCl

CAS No. 827022-32-2
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT02907918 Not yet recruiting Breast Cancer|Cancer of Breast|Breast Carcinoma Washington University School of Medicine|Pfizer February 28, 2017 Phase 2
NCT01209598 Completed Sarcoma|Liposarcoma Memorial Sloan Kettering Cancer Center|Pfizer September 23, 2010 Phase 2
NCT03054363 Not yet recruiting Breast Cancer University of Colorado, Denver March 2017 Phase 1|Phase 2
NCT03024489 Not yet recruiting Head and Neck Cancer|Locally Advanced|Unresectable Mahidol University February 2017 Phase 1|Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    There are two kind of Palbociclibs available: the isethionate salt or the HCl salt. I would like to know which is the main difference between them and what are they more suitable for in terms of experiment type (cell culture or in vivo animals experiments).

  • 回答:

    This two compounds are different Palbociclib salt. S1579 is the Isethionate salt, and the S1116 is the HCl salt. you can use S1116 for oral administration while S1579 is more suitable for I.P. administration.

Related Antibodies

CDK信号経路図

CDK Inhibitors with Unique Features

相関CDK製品

Tags: Palbociclib (PD-0332991) HClを買う | Palbociclib (PD-0332991) HCl ic50 | Palbociclib (PD-0332991) HCl供給者 | Palbociclib (PD-0332991) HClを購入する | Palbociclib (PD-0332991) HCl費用 | Palbociclib (PD-0332991) HCl生産者 | オーダーPalbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl化学構造 | Palbociclib (PD-0332991) HCl分子量 | Palbociclib (PD-0332991) HCl代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID